5-methyl-1,4,6-triamino-2(1H)-pyrimidinethione | 133889-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-methyl-1,4,6-triamino-2(1H)-pyrimidinethione
• 英文别名: 5-methyl-1,4,6-triaminopyrimidin-2-thione；1,4,6-Triamino-5-methylpyrimidine-2-thione
• CAS: 133889-95-9
• 化学式: C₅H₉N₅S
• 分子量: 171.226
• InChiKey: HYKOSOYKERUTOW-UHFFFAOYSA-N

物化性质

• 沸点：
  335.8±45.0 °C(Predicted)
• 密度：
  1.74±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methyl-1,4,6-triamino-2(1H)-pyrimidinethione 在 乙酸酐 作用下， 以 溶剂黄146 为溶剂， 生成 7-amino-1,2,8-trimethyl[1,2,4]triazolo[1,5-c] pyrimidine-5-thione
  参考文献：
  名称：

  Cephalosporin compounds and processes for the preparation thereof

  摘要：

  本发明涉及一种头孢菌素化合物，包括其药学上可接受的非毒性盐、生理水解酯、水合物和溶剂化合物，其分子式为(I)及其异构体：其中：R¹为C₁₋₄烷基、C₃₋₄烯基、C₃₋₄炔基或-C(Ra)(Rb)-COOH，其中Ra和Rb分别为氢或C₁₋₄烷基，或者共同形成与它们连接的碳原子一起的C₃₋₇环烷基；R²为氢或与氮原子连接的可取代或不可取代的氨基、烷氧基或杂环基团；R³为氢或C₁₋₄烷基、氨基、氨甲基、羟基、羟甲基、羧基或羧甲基基团；R⁴为氢或C₁₋₄烷基、氨基、羟基、羟基烷基、乙酰胺基、羧基烷基或磺酰乙基基团；R⁵为氢或C₁₋₄烷基、氨基、羧基、羧基烷基或羟基基团；Q和T独立地为CH或N，条件是当T为N时，R²为氨基团。

  公开号：

  EP0582261A1
• 作为产物：
  描述：

  1-异喹啉硼酸 、 氨基硫脲 以 乙醇 为溶剂， 以44%的产率得到5-methyl-1,4,6-triamino-2(1H)-pyrimidinethione
  参考文献：
  名称：

  Cephalosporin compounds

  摘要：

  本发明涉及新的头孢菌素化合物的公式(I)，其药学上可接受的非毒性盐，以及具有强大和广谱抗菌活性的生理水解酯和溶剂化合物。其中R.sup.1是C.sub.1到4烷基，C.sub.3到4烯基，C.sub.3到4炔基，或--C(R.sup.a)(R.sup.b)CO.sub.2 H.sub.1，其中R.sup.a和R.sup.b相同或不同，且每个都是氢原子或C.sub.1到4烷基，或R.sup.a和R.sup.b形成与它们连接的碳原子的C.sub.3到7环烷基；R.sup.2是C.sub.1到4烷基，C.sub.3到4烯基或C.sub.3到4环烷基，一个取代或未取代的氨基团，或一个取代或未取代的苯基；R.sup.3是氢或C.sub.1到4烷基；Q是N或CH。该发明还涉及制备所述化合物的方法，以及含有所述化合物的药物组合物。

  公开号：

  US05202315A1

文献信息

• Synthesis and Biological Activity of Novel Cephalosporins Containing a (Z)-Vinyl Dimethylphosphonate Group.
  作者：PAUL W. SMITH、ALBERT JAXA CHAMIEC、GAVIN CHUNG、KEVIN N. COBLEY、KEN DUNCAN、PETER D. HOWES、ANDREW R. WHITTINGTON、MIKE R. WOOD

  DOI：10.7164/antibiotics.48.73

  日期：——

  A series of cephalosporins containing a novel 7-[2-(Z)-(2-amino-thiazol-4-yl)-3-(dimethoxyphosphoryl)-acryloylamino] group were prepared and their antibacterial activity measured against a range of pathogens. In general the compounds displayed a broad spectrum of activity against both Gram positive and Gram negative organisms, except Pseudomonas aeruginosa. Activity against the latter could be achieved by introducing a catechol moiety at the 3 position of the cephalosporin. The methyl phosphonates in general were stable to a wide range of β-Mactamases, including the TEM enzymes and the Enterobacter cloacae P99 chromosomal enzyme. In addition, they showed the advantage of being highly water soluble.

  一系列含有新颖7-[2-(Z)-(2-氨基噻唑-4-基)-3-(二甲氧基磷酸酰基)-丙烯酰氨基]基团的头孢菌素被制备，并测量了它们对多种病原体的抗菌活性。一般来说，这些化合物对革兰阳性和革兰阴性生物表现出广谱活性，除了铜绿假单胞菌。通过在头孢菌素的3位引入儿茶酚基团，可以获得对后者的活性。总体而言，甲基膦酸酯对广泛的β-内酰胺酶，包括TEM酶和克雷伯菌P99染色体酶，表现出稳定性。此外，它们具有高度水溶性的优点。
• Cephalosporin compounds
  申请人：Lucky, Ltd.

  公开号：US05202315A1

  公开（公告）日：1993-04-13

  The present invention relates to new cephalosporin compounds of the formula(I), pharmaceutically acceptable non-toxic salts thereof, and physiologically hydrolyzable esters and solvates thereof, which have potent and broad antibacterial activities ##STR1## wherein R.sup.1 is a C.sub.1.about.4 alkyl, C.sub.3.about.4 alkenyl, C.sub.3.about.4 alkynyl group, or --C(R.sup.a)(R.sup.b)CO.sub.2 H.sub.1 wherein R.sup.a and R.sup.b are the same or different, and each is a hydrogen atom or a C.sub.1.about.4 alkyl group, or R.sup.a and R.sup.b form a C.sub.3.about.7 cycloalkyl group with the carbon atom to which they are linked; R.sup.2 is a C.sub.1.about.4 alkyl, C.sub.3.about.4 alkenyl or C.sub.3.about.4 cycloalkyl group, a substituted or unsubstituted amino group, or a substituted or unsubstituted phenyl group; R.sup.3 is hydrogen or a C.sub.1.about.4 alkyl group; and Q is N or CH. The invention further relates to a process for preparing said compounds, and to pharamaceutical compositions containing said compounds.

  本发明涉及新的头孢菌素化合物的公式(I)，其药学上可接受的非毒性盐，以及具有强大和广谱抗菌活性的生理水解酯和溶剂化合物。其中R.sup.1是C.sub.1到4烷基，C.sub.3到4烯基，C.sub.3到4炔基，或--C(R.sup.a)(R.sup.b)CO.sub.2 H.sub.1，其中R.sup.a和R.sup.b相同或不同，且每个都是氢原子或C.sub.1到4烷基，或R.sup.a和R.sup.b形成与它们连接的碳原子的C.sub.3到7环烷基；R.sup.2是C.sub.1到4烷基，C.sub.3到4烯基或C.sub.3到4环烷基，一个取代或未取代的氨基团，或一个取代或未取代的苯基；R.sup.3是氢或C.sub.1到4烷基；Q是N或CH。该发明还涉及制备所述化合物的方法，以及含有所述化合物的药物组合物。
• Cephalosporin compounds and processes for the preparation thereof
  申请人：LUCKY LTD.

  公开号：EP0582261A1

  公开（公告）日：1994-02-09

  The present invention relates to a cephalosporin compound including the pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates thereof of the formula(I) and its isomers: wherein: R¹ isa C₁₋₄ alkyl, C₃₋₄ alkenyl, C₃₋₄ alkynyl or -C(Ra)(Rb)-COOH wherein Ra and Rb are, independently of each other, a hydrogen or a C₁₋₄ alkyl group, respectively, or jointly form a C₃₋₇ cycloalkyl group together with the carbon atoms to which they are attached; R² isa hydrogen or an amino which may be substituted or unsubstituted, alkoxy or heterocyclic group which is linked with a nitrogen atom; R³ isa hydrogen or a C₁₋₄ alkyl, amino, aminomethyl, hydroxy, hydroxymethyl, carboxy or carboxymethyl group; R⁴ isa hydrogen or a C₁₋₄ alkyl, amino, hydroxy, hydroxyalkl, acetamide, carboxyalkyl or sulfonylethyl group; R⁵ isa hydrogen or a C₁₋₄ alkyl, amino, carboxy, carboxyalkyl or hydroxy group; and Q and T areindependently CH or N, provided that R² is an amino group when T is N.

  本发明涉及一种头孢菌素化合物，包括其药学上可接受的非毒性盐、生理水解酯、水合物和溶剂化合物，其分子式为(I)及其异构体：其中：R¹为C₁₋₄烷基、C₃₋₄烯基、C₃₋₄炔基或-C(Ra)(Rb)-COOH，其中Ra和Rb分别为氢或C₁₋₄烷基，或者共同形成与它们连接的碳原子一起的C₃₋₇环烷基；R²为氢或与氮原子连接的可取代或不可取代的氨基、烷氧基或杂环基团；R³为氢或C₁₋₄烷基、氨基、氨甲基、羟基、羟甲基、羧基或羧甲基基团；R⁴为氢或C₁₋₄烷基、氨基、羟基、羟基烷基、乙酰胺基、羧基烷基或磺酰乙基基团；R⁵为氢或C₁₋₄烷基、氨基、羧基、羧基烷基或羟基基团；Q和T独立地为CH或N，条件是当T为N时，R²为氨基团。